Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Cora N. Sternberg,Karim Fizazi,Fred Saad,Neal D. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Petro Ivashchenko,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel de Iracema Gomes Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain

Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

2020

Cora N. Sternberg
Karim Fizazi
Fred Saad
Neal D. Shore
Ugo De Giorgi
David F. Penson
Ubirajara Ferreira
Petro Ivashchenko
Eleni Efstathiou
Katarzyna Madziarska
Michael Kolinsky
Daniel de Iracema Gomes Cubero
Bettina Noerby
Fabian Zohren
Xun Lin
Katharina Modelska
Jennifer Sugg
Joyce Steinberg
Maha Hussain

5515Background: PROSPER previously demonstrated a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) (hazard ratio [HR] 0.29; 95% CI 0.24-0.35; P < .0...

Keywords:

Oncology
Enzalutamide
Physical therapy
double blind
overall survival
Prostate cancer
castration resistant
Placebo
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations